eEF1A2 (eukaryotic protein elongation factor 1 alpha 2) is a protein translation factor that is likely a human oncogene by virtue of its capacity to transform mammalian cells and its high expression in tumors of the ovary, breast and lung. Here, we show that expression of eEF1A2 is sufficient to stimulate the formation of filopodia in BT549 human breast cancer cells and non-transformed Rat2 cells. Filopodia formation in eEF1A2-expressing cells is dependent on the activity of phosphatidylinositol-3 kinase (PI3K), and the ROCK and Akt kinases. Furthermore, eEF1A2 expression is sufficient to activate Akt in a PI3K-dependent fashion and inactivation of eEF1A2 by short interfering RNA reduces Akt activity. Using breast cancer cell line BT 549, we show that eEF1A2 expression stimulates cell migration and invasion in a largely PI3K-and Akt-dependent manner. These results suggest that eEF1A2 regulates oncogenesis through Akt and PI3K-dependent cytoskeletal remodeling.
Introduction eEF1A2 (eukaryotic protein elongation factor 1 alpha 2) is one of the two isoforms of protein elongation factor eEF1A (eEF1A1 and eEF1A2). eEF1A proteins are GTP-binding proteins that interact with amino-acylated tRNA and recruit them to the ribosome during the elongation phase of protein translation. The two human isoforms share >90% identity and have essentially the same function during protein translation (Knudsen et al., 1993) . eEF1A1 is expressed ubiquitously whereas mammalian eEF1A2 expression is limited to the heart, brain and skeletal muscle (Knudsen et al., 1993; Lee et al., 1993; Kahns et al., 1998) .
eEF1A2 is likely to be an important human oncogene (Lee, 2003) . EEF1A2, the gene encoding eEF1A2, is amplified and its mRNA overexpressed in B30% of primary human ovarian cancers (Anand et al., 2002) . Expression of wild-type eEF1A2 transforms rodent fibroblasts and increases their tumorigenicity in nude mice (Anand et al., 2002) . Amplification of EEF1A2 and increased eEF1A2 mRNA and protein overexpression has also been reported in lung and breast tumors (Wang et al., 2004; Tomlinson et al., 2005; Kulkarni et al., 2006) . In lung cancer, high expression of eEF1A2 correlates with increased Ki-67 expression and is associated with poor prognosis (Wang et al., 2004) . Furthermore, eEF1A2 may also have a role in metastatic development and it is overexpressed in metastatic rat mammary adenocarcinoma cell lines relative to nonmetastatic controls (Pencil et al., 1993; Edmonds et al., 1996) . Although these observations implicate eEF1A2 in oncogenesis, little is known about the molecular mechanisms by which eEF1A2 could enhance tumor development.
eEF1A proteins have cellular functions in addition to their canonical role in translation elongation. eEF1A from several species and genera binds to actin filaments and microtubules both in vivo and in vitro (Condeelis, 1995) . Binding of Dictyostelium eEF1A to F-actin enhances actin bundling (Yang et al., 1990) , suggestive of a role for eEF1A in actin cytoskeleton remodeling. Two C-terminal domains in the Dictyostelium eEF1A protein directly bind actin (Condeelis, 1995) . These domains are distinct from sequences that bind GTP, tRNA or are responsible for GTP hydrolysis. Saccharomyces cereviseae has two eEF1A genes (TEF1 and TEF2), both of which more closely resemble human eEF1A1 than eEF1A2 gene. TEF1 proteins that are deficient in actin bundling are competent in translation elongation, indicating that actin interaction and peptide elongation are independent functions of the protein (Gross and Kinzy, 2005) . Although ectopic TEF1 or TEF2 expression in S. cereviseae leads to a general disorganization of the actin cytoskeleton (Munshi et al., 2001) , the effect that mammalian eEF1A2 expression has on the eukaryotic actin cytoskeleton has yet to be fully investigated.
eEF1A proteins have also been implicated in phosphatidylinositol (PI) signaling. PIs are negatively charged, low-abundant, membrane-bound phospholipids that serve as regulators of multiple signaling pathways (Carpenter and Cantley, 1990; Fruman et al., 1998; Overduin et al., 2001; Meijer and Munnik, 2003 ). An eEF1A-related protein, PIK-A49, has been purified from carrot cells based on an ability to increase the in vitro lipid kinase activity of phosphatidylinositol-4 kinase (PI4K) (Yang et al., 1993) . PI4Ks catalyse the phosphorylation of the D4 carbon of the inositol ring PI (Heilmeyer et al., 2003) . Phosphatidylinositol-4 phosphate is an obligate precursor of phosphatidylinositol-(4,5) biphosphate and phosphatidylinositol-(3,4,5) triphosphate (PIP 3 ). PIP 3 is a lipid second messenger that activates diverse signaling pathways important in oncogenesis, among them activation of the Akt serine/ threonine kinase (Vivanco and Sawyers, 2002) . Akt directly and indirectly controls the activity of many oncogenic pathways, including proliferation, growth, apoptosis and actin filament remodeling (Vivanco and Sawyers, 2002; Qian et al., 2004) . Recently, eEF1A1 has been determined by mass spectroscopy to be a possible binding partner for Akt2 and ectopic eEF1A2 expression has been shown to increase Akt abundance (Lau et al., 2006) . However, functional aspects of eEF1A/Akt interaction remain unexplored.
In this report, we find that eEF1A2 is a novel activator of Akt. Akt activation by eEF1A2 is dependent on PI3K. Furthermore, eEF1A2 induces filopodia production in rodent and human cell lines and enhances cell invasion and migration in an Akt-and PI3K-dependent manner. This indicates an important role for eEF1A2 in controlling phosphatidylinositol signaling, actin remodeling and cell motility.
Results

eEF1A2 expression induces rearrangement of the actin cytoskeleton
To examine a role for eEF1A2 in actin remodeling, we ectopically expressed eEF1A2 in cell lines that normally do not express eEF1A2. As shown in Figure 1a , eEF1A2 protein is expressed in the monocyte chemoattractant factor-7 (MCF-7) human breast adenocarcinoma line, but is not detectable in the BT549 human breast ductal carcinoma cancer cell line nor the rat Rat2 nontransformed fibroblast line. eEF1A2 protein is also detectable in the rat ovarian epithelial ROSE 199 cell line ( Figure 1a , right panel) (Adams and Auersperg, 1985) . The eEF1A2 antibody used for this analysis recognizes an eEF1A2 epitope (KVERKEGNASGVSL-LEALDT) that is identical between the rat and the human eEF1A2 isoforms (Kulkarni et al., 2006) . High expression level of eEF1A2 protein was detected in selected cell lines (Figure 1b ). Cells infected with empty pLXSN or transfected with an empty pCDNA3.1 vector were used as controls.
To examine a role for eEF1A2 in controlling the actin cytoskeleton, we stained eEF1A2-expressing cells and controls with phalloidin. Control BT549 cells showed prominent actin stress fibers, a thin but recognizable lamellipodia, but very few filopodia-like structures (Figure 2a ). Filopodia are pencil-like bundles of parallel actin fibers that emerge from the cell lamellipod. Filopodia exist in many cell types and have a role in activating and sustaining cell migration (Carragher and Frame, 2004; Chodniewicz and Klemke, 2004) . eEF1A2-expressing BT549 cells showed a dramatic increase in the number and length of filopodia-like structures emerging from the lamellipod (Figure 2a ). These filopodia are >10 mM in length. Filopodia in control BT549 cells, when present, were o1 mM. In many eEF1A2-expressing cells, the filopodia are not only greater in number but also exhibit branching as they project outward. Branched filopodia were not observed in any control BT549 cells. Filopodia structures in the eEF1A2-expressing cells are somewhat polarized, meaning that they are often longer and more branched at one of eEF1A2 expression. Human BT549 and rat Rat2 cells do not naturally express eEF1A2 whereas human MCF7 breast cancer and rat ROSE 199 cells do express eEF1A2 protein. Expression was measured using an eEF1A2-specific antibody. (b) Stable expression of eEF1A2 protein in BT549 and Rat2 cell lines. 1A2-1, 1A2-2, 1A2-3, 1A2-A and 1A2-B refer to clonal cell lines. 1A2-polyclonal and Rat2-1A2 are cell lines derived from pooling several (>10) drug-resistant colonies after selection. The expression of eEF1A2 was analysed by immunoblotting using anti-eEF1A2 or anti-V5 antibodies. Actin was used as a loading control. eEF1A2-expressing BT549 cells were generated using a plasmid vector or a retrovirus.
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A Amiri et al side of the cell (Figure 2a ). Increased filopodia number and length was observed in all eEF1A2-expressing BT549 clones, independent of whether they were made by retroviral infection or plasmid transfection. This indicates that observed eEF1A2-dependent actin remodeling is unlikely to be owing to chance clonal variation. To further confirm that the increase in filopodia formation was dependent on eEF1A2, we inhibited eEF1A2 by adding eEF1A2 short interfering RNA (siRNA) to eEF1A2-expressing BT549 cells. Using this siRNA, we are generally able to reduce the eEF1A2 level by B90% relative to control siRNA ( Figure 2b ). Addition of eEF1A2 siRNA resulted in a reduction in filopodia formation relative to control siRNA ( Figure 2c ). To determine whether eEF1A2 could induce filopodia formation in other cell types, we next expressed eEF1A2 in non-transformed rodent Rat2 cells. Rat2 does not express detectable eEF1A2 protein (Figure 1a) . Like BT549 cells, eEF1A2 expression activated the appearance of filopodia structures in Rat2 cells (Figure 2d ). Filopodia were not observed in control Rat2 cells. No discernable alteration in lamellipodia or stress fibers was observed upon eEF1A2 expression. The ability of eEF1A2 to induce filopodia formation in both transformed (BT549) and non-transformed (Rat2) cell lines indicate that eEF1A2's effect on actin remodeling is unlikely to be cell-line specific.
To further characterize eEF1A2-induced filopodia, we observed their formation by video time-lapse microscopy. As shown in Figure 3a , filopodia were visible by light microscopy only in eEF1A2 expressing cells. These filopodia protruded outward from the eEF1A2-expressing cell in the general direction of cell movement, indicating that they do not derive from cytoplasmic retraction (Figure 3a) . To further study the filopodia structures, we stained eEF1A2-expressing BT549 cells with a VASP antibody and phalloidin ( Figure 3b ). VASP is a member of the Ena (Drosophila enabled)/VASP (vasodilator-stimulated phosphoprotein) eEF1A2 activates Akt and actin remodeling A Amiri et al proteins, which are localized to focal adhesions, along stress fibers and at the tips of lamellipodia and many filopodia (Reinhard et al., 1992; Svitkina et al., 2003) . VASP is a key player in the formation of filopodia. In eEF1A2-expressing cells, VASP was mostly detectable at the base of the filopodia and between and within the actin fibers.
eEF1A2-dependent actin reorganization requires P13K, Akt and ROCK activity PI3K is involved in many cellular processes, including growth, survival and actin filament remodeling (Vivanco and Sawyers, 2002) . To test the hypothesis that eEF1A2 may regulate filopodia through PI3K-dependent signaling, we added LY294002, a specific inhibitor of PI3K to eEF1A2-expressing cells and observed filopodia formation. As shown in Figure 4a and b, addition of LY294002 reduced the size and number of filopodia structures in both Rat2 and BT549 cells. This reduction was dose-dependent: filopodia shorten to o5 mM in 10 mM LY294002 and branching is reduced in both Rat2 and BT549 cells. LY294002 (20 mM) reduced filopodia number to wild-type levels in both cells. LY294002 had no visible effect on lamellipodia or stress fibers. These observations indicate that PI3K activity is required for actin filament rearrangement induced by eEF1A2.
As filopodia formation is dependent on PI3K, we next determined eEF1A2 could directly bind PI3K or was an activator of PI3K activity. To this end, we transiently expressed eEF1A2 in BT549 cells using an eEF1A2-adenovirus. As shown in Figure 4c , ectopically expressed eEF1A2 did not co-immunoprecipitate with Figure 4d ). PI3K activity was measured by phosphorylation of tyrosine 506 (Y508), the p85 subunit of PI3K, a marker for P13K activity (Chen et al., 2004) . A key target of PI3K is Akt. Akt is involved in many biological processes, among them are proliferation, does not physically interact with PI3K. BT549 cells were infected with an adenovirus for GFP or eEF1A2 or mock infected. Antibodies for either eEF1A2 or PI3K were used for immunoprecipitation (IP) from whole cell lysates. An anti-V5 antibody is used as an IP control. Co-immunoprecipitating proteins were detected by WB using antibodies specific for eEF1A2 and PI3K. The whole-cell lysate lane (WCL) contains 100 mg of total cellular protein and each IP was performed using 100 mg of protein lysate. (d) eEF1A2 does not activate PI3K. BT549 cells were infected with an Adenovirus for GFP or eEF1A2 and the levels of the indicated proteins assayed by WB. PI3K activation is measured by phosphorylation of tyrosine 508 (e and f) cells were treated with 1 mM API-2, an Akt inhibitor (e) or 10 mM Y27632, a ROCK kinase inhibitor overnight and stained with phalloidin. Vehicles applied to control cells. apoptosis and growth (Vivanco and Sawyers, 2002) . It has also been shown that PI3K remodels actin filaments through the activation of Akt (Qian et al., 2004) . To test whether Akt is also involved in filopodia formation by eEF1A2, we used Acute Panic Inventory-2 (API-2), a specific inhibitor of Akt (Yang et al., 2004) to eEF1A2-expressing cells. As shown in Figure 4e , addition of API-2 greatly reduced the formation of filopodia in eEF1A2-expressing BT549 cells, indicating that Akt is required for eEF1A2-dependent filopodia formation.
Recently, it has been shown that PI3K regulates filopodia dynamics through Akt and ROCK (Tornieri et al., 2006) . ROCK kinase is a downstream effector of the RhoA GTPase (Riento and Ridley, 2003) . To investigate whether Rho signaling has any role in the formation of filopodia by eEF1A2, we used ROCK inhibitor Y27632. As shown in Figure 4f , addition of Y27632 decreased the number and length of filopodia to the wild-type level in eEF1A2-expressing BT549 cells, suggesting the importance of ROCK kinase in the formation of filopodia by eEF1A2.
Expression of eEF1A2 is sufficient to activate Akt in a PI3K-dependent manner As filopodia production by eEF1A2 was, at least in part, dependent on Akt activity, we determined whether eEF1A2 might be involved in Akt activation. Akt is activated by its membrane translocation and phosphorylation at Thr 308 and Ser 473. Thus, phosphorylations of Thr 308 and Ser 473 serve as surrogate markers of Akt activation. To determine whether the expression of eEF1A2 has any effect on Akt activation, we transiently expressed eEF1A2 in BT549 cells using an eEF1A2-adenovirus and then used Western blotting to determine the phosphorylation status of Thr 308 and Ser 473. As shown in Figure 5a , infection of eEF1A2 increased phosphorylation of both Thr 308 and Ser 473 relative to GFP-infected cells. Moreover, BT549 cells that stably express eEF1A2 also showed increased levels of phosphorylation at both Thr 308 and Ser 473 sites relative to control cells (Figure 5b ). We next used siRNA to inactivate eEF1A2 in MCF7 breast cancer cells. Endogenous eEF1A2 is readily detectable in wildtype MCF7 cells (Figure 1a) . In these cells, eEF1A2 siRNA reduced Akt phosphorylation somewhat (1.8 when normalized to actin). Inhibition of Akt activity was not complete, suggesting that as eEF1A2 has a physiological role in controlling Akt activity, there are likely to be eEF1A2-independent pathways of Akt activation. To determine whether Akt activation by eEF1A2 was dependent on PI3K activity, we treated eEF1A2-overexpressing BT549 cells with LY294002. As shown in Figure 5d , LY294002 inhibited the activation of Akt in a dose-dependent manner. However, addition of rapamycin, an inhibitor of mTOR/Raptor complex, The indicated clones of eEF1A2-expressing BT549 cells were serum-starved overnight and placed in a transwell migration chamber. The photographs show a representative field from each of the cell lines that have migrated into the chamber. In the lower panel, migration is expressed as a percentage of vector only controls and is the mean and s.d. of triplicate independent experiments. Enhanced migration is statistically significant (Po0.05, Students's t-test) and marked by an asterisk. (b) eEF1A2-induced migration is inhibitable by PI3K inhibition. Indicated eEF1A2-expressing BT549 cells were serumstarved overnight, and incubated with LY294002 for 2 h at the indicated concentrations before being placed in the transwell chamber. The micrographs show a representative field of cells that have migrated into the chamber. In the lower panel, migration is expressed as a percentage of vector only controls and is the mean and s.d. of triplicate independent experiments each with triplicate counts. (c) eEF1A2-expressing BT549 cells were treated with 1 mM API-2 (overnight), 10 ng/ml rapamycin (2 h) or 10 nM wortmannin (30 min) and subjected to cell migration as above. As control cells were treated with vehicles only, migration is expressed as a percentage of vector only controls and is the mean and s.d. of triplicate independent experiments, each with triplicate counts. Migration inhibition is statistically significant (Po0.05, Students's t-test) and marked by an asterisk.
A Amiri et al had no affect on Akt activation by eEF1A2 (Figure 5e ). Taken together, our results indicate that eEF1A2 is a functional regulator of Akt activity.
Expression of eEF1A2 increases cell migration Filopodia structures are critical for cell migration and invasion (Chodniewicz and Klemke, 2004) and activation of Akt has been reported previously to increase cell migration and invasion (Arboleda et al., 2003) . Enhanced formation of filopodia and Akt activation in eEF1A2-overexpressing cells suggests that eEF1A2 might be involved in both migration and invasion. To assess whether overexpression of eEF1A2 is sufficient to increase cell migration, we measured the migration of BT549 cells using transwell migration assays. As shown in Figure 6a , eEF1A2 expression significantly enhanced eEF1A2 activates Akt and actin remodeling A Amiri et al cell migration relative to control cells (Student's t-test, Po0.05). To determine whether PI3K activity is required for this increase in cell migration, we measured migration in the presence of LY294002. As shown in Figure 6b , PI3K inhibition reduced the extent of migration significantly in eEF1A2-expressing cells (Student's t-test, Po0.05). However, the magnitude of this migration in the presence of 20 mM LY294002 was still higher than the control, and increasing LY294002 dosage had no further inhibitory effect on migration but did cause cytotoxicity (data not shown). To investigate whether Akt has any effect on the cell migration by eEF1A2, we added Akt inhibitor, API-2, to the BT549 cells overexpressing eEF1A2. As in the case of LY294002 and wortmannin, addition of API-2 significantly reduced cell migration (Student's t-test, Po0.05), but it did not completely abolish it to the same level as control cells (Figure 6c) . Similarly, addition of wortmannin, another PI3K inhibitor, at the concentration of 10 nM significantly (Student's t-test, Po0.05)
decreased the magnitude of cell migration in eEF1A2-expressing cells (Figure 6c ). These results suggest that activation of PI3K and Akt is important in eEF1A2-induced cell migration.
Expression of eEF1A2 is sufficient to increase cell invasion To investigate a role for eEF1A2 in invasion, we coated transwells with Matrigel to simulate the basal lamina. As shown in Figure 7 , significantly (Student's t-test, Po0.05) more eEF1A2-expressing cells invaded through the matrix than control cells, suggesting that eEF1A2 is an enhancer of cell invasion. Furthermore, this enhanced invasion in eEF1A2-expressing cells was significantly (Student's t-test, Po0.05) inhibited by LY294002 and API-2, indicating a dependence of eEF1A2-induced invasion on PI3K and Akt activities (Figure 7a and b) . However, like the case with eEF1A2-induced migration by LY294002/wortmannin or API-2 never completely reduced invasion to wild-type levels, Figure 7 eEF1A2 expression increases cell invasion. eEF1A2-overexpressing BT549 were serum-starved overnight. After preincubation with LY294002 or DMSO (vehicle) for 2 h, cells were subjected to the invasion assay using Matrigel-coated transwells for approximately 48 h. The photographs show a representative field from each of the cell lines that have invaded through the Matrigel. In the lower panel, invasion is expressed as a percentage of vector only controls and is the mean and s.d. of triplicate independent experiments with triplicate counts. Enhanced migration of 1A2 relative to the vector only control is statistically significant (Po0.05, Students's t-test) and marked by a single asterisk. Similarly, the ability of LY294002 to attenuate invasion inhibition is statistically significant (Po0.05, Students's t-test) and marked by a double asterisk. (b) eEF1A2-expressing BT549 cells were treated with 1 mM API-2 (overnight), 10 ng/ml rapamycin (2 h) or 10 nM wortmannin (30 min) and subjected to cell invasion as above. As control cells were treated with vehicles only, invasion is expressed as a percentage of vector only controls and is the mean and s.d. of triplicate independent experiments, each with triplicate counts. Invasion inhibition is statistically significant (Po0.05, Students's t-test) and marked by a single asterisk.
eEF1A2 activates Akt and actin remodeling A Amiri et al suggesting the existence of PI3K-independent pathways through which eEF1A2 stimulates invasion and migration. Addition of mTOR/Raptor inhibitor, rapamycin, had no effect on either cell migration or invasion by eEF1A2, indicating that mTOR/Raptor pathway is not involved in these processes (Figures 6c and 7b) .
Expression of eFF1A2 has no effect on spreading and adhesion Cell adhesion and spreading are cellular processes that occur during cell migration. To determine whether eEF1A2 had any effect on cell spreading, we used video microscopy to observe the behavior of BT549 cells on fibronectin-coated plates. eEF1A2-expressing cells and controls were trypsinized, plated and observed for lamellipodia formation. As shown in Figure 8a , by 10 min, control cells begin to form a visible lamellipod (arrow) and by 28 min have developed large lamellipodia. eEF1A2-expressing cells formed a lamellipod with similar kinetics, indicating that eEF1A2 expression is not affecting cell spreading, as measured by lamellipod formation. This result is consistent with our observation (Figure 2 ) that eEF1A2 does not affect lamellipodia appearance. To determine whether eEF1A2 affected cell adhesion, we trypsinized BT549 cells and added them to fibronectin-coated coverslips. At various times after cell addition, coverslips were washed and fixed to remove the unstably attached or detached cells and to observe cells that had strongly adhered to their growth substrate. The number of adhering cells therefore serves as an indirect measure of cell adhesion. As shown in Figure 8b , control and eEF1A2-expressing cells had similar adhesive parameters. Thus, eEF1A2 detectably affects neither cell spreading nor the kinetics of the adhesion process.
Discussion eEF1A2, protein elongation factor eEF1A2, is likely to be an important oncogene (Thornton et al., 2003) . eEF1A2 is highly expressed in 30-60% of tumors of the ovary, breast and lung (Lee, 2003; Li et al., 2005; Tomlinson et al., 2005; Kulkarni et al., 2006) . Wild-type eEF1A2 has transforming properties: it enhances focus formation, allows growth in soft agar and increases the tumorigenicity of mouse and human cells in nude mice (Anand et al., 2002) . However, the mechanism by which eEF1A2 induces oncogenesis is unclear. Here, we show that eEF1A2 activates the Akt serine/threonine kinase and stimulates actin remodeling that is dependent on PI3K, Akt and ROCK. eEF1A2 expression also makes cells more motile and invasive in vitro. We propose that eEF1A2 promotes tumor development through PI3K-dependent activation of Akt and an Akt-dependent increase in filopodia formation and motility. eEF1A2 is one of two isoforms of eEF1A, eEF1A1 and eEF1A2. eEF1A proteins are relatively well conserved during evolution, and eEF1A homologes have been identified in yeast and Caenorhabditis elegans, among others. Beyond its role in translation, eEF1A has additional cellular functions. Interaction of eEF1A with Figure 8 eEF1A2 expression has no effect on cell spreading and adhesion. (a) eEF1A2 expressing cells were trypsinized, and placed on a growth substrate containing fibronectin and observed as a function of time using time-lapse video microscopy on a heated stage. White arrows mark the first appearance of lamellipodia in the plated cells. (b) Cells were trypsinized and plated onto fibronectin-coated coverslips. At indicated time points, cells were washed with PBS, fixed using 3.7% formaldehyde and adherent cells were counted.
eEF1A2 activates Akt and actin remodeling A Amiri et al the actin cytoskeleton was first demonstrated in Dictyostelium (Yang et al., 1990) and eEF1A proteins of several animal genera have been reported to bind F-actin and bundle them in vitro (Yang et al., 1990; Edmonds et al., 1996; Munshi et al., 2001) . There are two S. cerevisiae eEF1A homologues (TEF1, TEF2); both are more related to eEF1A1 than eEF1A2. In the Tef1 protein, actin bundling and translation elongation are separable enzymatic activities because Tef1 point mutations that inhibit actin binding and bundling have no substantial effect on the translation (Gross and Kinzy, 2005) . The two functions are also physically separate on the eEF1A protein: two domains in the C-terminus of eEF1A bind actin whereas the GTP binding, hydrolysis and tRNA interacting domains are found in the eEF1A N-terminus (Hershey, 1991; Condeelis, 1995) . Ectopic expression of Tef1 or Tef2 proteins in S. cereviseae reduces the accumulation of F-actin structures at the bud (Munshi et al., 2001) but the effect of eEF1A on the actin cytoskeleton of mammalian cells has not been reported previously. We find that eEF1A2 expression increases the formation of filopodia structures in rodent and human cells. Filopodia are bundles of parallel actin that protrude outward from the cell membrane. Protrusive actin structures have an important role in driving cell migration and invasion, particularly in metastatic tumor cells (Yamaguchi et al., 2005) . Consistent with an involvement of filopodia in cell movement, we found that eEF1A2 causes cells to be more migratory and invasive in vitro.
The increased invasiveness of eEF1A2-expressing cells suggests that eEF1A2 might have a role in tumor metastasis. In fact, eEF1A has been reported previously to be overexpressed in metastatic rat mammary adenocarcinoma cell lines compared to non-metastatic ones (Pencil et al., 1993; Edmonds et al., 1996) . As metastatic development is the ultimate cause of death in cancer, the ability of eEF1A2 to increase migration predicts that eEF1A2-expression would be associated with poor prognosis. Consistent with this idea, lung cancer patients whose tumor have high levels of eEF1A2 have a reduced probability of survival compared to their noneEF1A2-expressing counterparts (Li et al., 2005) . In addition, high eEF1A2 expression is associated with severe tumor grades and metastasis in several cancer cell lines (Pencil et al., 1993; Edmonds et al., 1996; Li et al., 2005) . We have recently determined the prognostic significance of eEF1A2 in breast cancer (Kulkarni et al., 2006) . To our astonishment, we find that high eEF1A2 protein expression correlates with an increased probability of 20-year survival (Kulkarni et al., 2006) . eEF1A2 expression is independent of other breast cancer prognostic factors. It is a surprise to us that expression of an Akt activator and an enhancer of cell migration correlates with enhanced survival probability. For example, expression of Snail, an inducer of cell migration, correlates with poor survival in breast cancer (Moody et al., 2005) . Because of its transforming capacity and its high tumor-specific expression, eEF1A2 is likely to be promoting tumor growth in breast cells.
However, we speculate that though eEF1A2 may activate several oncogenic processes (i.e. Akt activation and enhancing migration), it may be a less potent breast cancer oncogene than others. Alternatively, eEF1A2 may alter some malignant process that inhibits patient mortality. For example, a capacity for eEF1A2 to promote cell proliferation may make the tumor more susceptible to chemotherapy or eEF1A2 expression may drive tumor cells into a more differentiated and therefore less malignant state. Possibly, the enhancement of motility by eEF1A2 may preclude the successful colonization of metastatic sites because migratory cells that leave the primary tumor may be too motile to stably colonize secondary sites. The observation that eEF1A2 expression is a marker of good prognosis in the breast (Kulkarni et al., 2006) and a marker of poor prognosis in the lung (Li et al., 2005) may reflect the different microenvironments and physiology of these two malignancies.
The PI3K and Akt pathway regulates many cellular processes, including cell adhesion, proliferation, survival and cytoskeletal rearrangement (Vivanco and Sawyers, 2002) . Our observation that eEF1A2 activates Akt suggests a plausible explanation for the capacity of eEF1A2 to transform cells in vitro and suggests that eEF1A2 promotes tumor development through Akt. Furthermore, we find that the capacity of eEF1A2 to stimulate cell migration is Akt dependent. Overexpression of Akt2 has been shown to increase invasion and metastasis in human breast and ovarian cancer cells in a PI3K-dependent manner (Arboleda et al., 2003) . The mechanism by which eEF1A2 could activate Akt is unknown, although we speculate that phosphatidylinositol signaling is involved (see below). Akt2 has recently been identified as an interacting partner of eEF1A1 (Lau et al., 2006) . It is therefore possible that binding of eEF1A1 or eEF1A2 to Akt may directly activate the kinase, although the biological significance of eEF1A1/Akt interaction has yet to be determined. It is also unknown whether eEF1A2 directly binds any Akt isoform. Chang and Wang (2006) found that overexpression eEF1A2 in mouse NIH 3T3 fibroblast cells resulted in increase of the Akt level in these cells. However, we did not see any increase in the steady state of Akt levels in BT 549 breast cancer cells or Rat2 cell. Although a role for eEF1A2 in controlling Akt abundance is possible, eEF1A2 does not alter steadystate Akt levels in our hands.
We have found that induction of filopodia by eEF1A2 is dependent on PI3K, Akt and ROCK signaling. The ability of eEF1A2 to activate migration and invasion in breast cancer cells in vitro is largely, but not completely, PI3K-dependent. Therefore, eEF1A2 is likely to be involved in both PI3K-dependent and independent pathways that control filopodia formation and cell migration and invasion. Overexpression of PI3K has been shown to cause an increase of both lamellipodia and filopodia formation in chicken embryo fibroblast cells as well as a decrease of actin stress fibers (Qian et al., 2004) . Akt has been postulated to modulate actin remodeling through two substrates: Girdin eEF1A2 activates Akt and actin remodeling A Amiri et al (Enomoto et al., 2005) and Pak1 (Zhou et al., 2003) . Girdin is an actin bundling protein (Enomoto et al., 2005) and Pak1 is a member of the PAK (p21-activated kinase) family serine/threonine kinases that phosphorylate several proteins that directly or indirectly stimulate actin remodeling (Kumar et al., 2006) . In the future, it will be interesting to determine whether Girdin or Pak1 is involved in eEF1A2-dependent filopodia formation. Our study shows that eEF1A2 overexpression only affects filopodia but not lamellipodia or stress fiber formation in a PI3K/Akt-dependent manner. The ability of eEF1A2 to activate filopodia only indicates that eEF1A2 does not regulate all types of actin structures in mammalian cells. Although eEF1A proteins from yeast and Dictyostelium have been reported to have actin bundling activity, it is not clear whether eEF1A2 regulates filopodia by directly bundling actin. It has been suggested, however, that eEF1A cross-links actin filaments in a way that exclude other proteins to crosslink F-actin (Owen et al., 1992) , suggesting a direct interaction between eEF1A2 and actin filaments. Because eEF1A2 induction of filopodia is dependent on PI3K, eEF1A2 may regulate actin rearrangement not through direct actin bundling but through phosphoinositide-dependent signaling. The dependence of eEF1A2 induction of filopodia on ROCK as well as PI3K is consistent with this idea. Because ROCK is a Rho effector and Rho activity is dependent on PI3K, we hypothesize that eEF1A2 activates actin rearrangement by stimulating PI(3,4,5)P generation and activating ROCK through Rho A. Because we find that the eEF1A2-dependent activation of Akt is dependent on PI3K activity, we also propose that Akt activation by eEF1A2 is via PIP 3 generation.
A role for eEF1A proteins in phospho-inositol signaling has been suggested previously by the identification of the carrot eEF1A homologe PIK-A49 as direct activator of PI4K (Yang et al., 1993) . Because PIK-A49 has not been cloned as a full-length complementary DNA (cDNA), it is unclear whether PIK-A49 is a bona fide eEF1A gene, but protein sequences of PIK1A9 have a high homology to eEF1A proteins from multiple species. Because PI4K activity has the potential to regulate the downstream abundance of important lipid second messengers PI(4,5)P and PI(3,4,5)P, eEF1A2 may also activate filopodia formation through activation of PI(3,4,5)P abundance by increasing PI4K activity. A recent report by Pendaries et al. (2006) indicate that PI5P created by the Shigella parasite can activate Akt in a PI3K-dependent fashion, suggesting that phospholipids abundance may activate PI3K-dependent signaling . It is possible that eEF1A2 may enhance PI (3,4,5)P generation by activating PI4K. Recent identification of Akt2 as a potential interacting partner of eEF1A1 and Fascin (an actin bundling protein) and mRif (mouse Rho in filopodia) as eEF1A2-binding proteins (Chang and Wang, 2006; Lau et al., 2006) suggest that eEF1A2 controls filopodia formation by bringing a complex of actin and PI4K/ Akt/Rho signaling proteins together.
The two human eEF1A isoforms (eEF1A2 and eEF1A2) are very similar proteins (92% amino-acid identity). The two isoforms appear to have the same activity in protein elongation (Kahns et al., 1998) . However, it has yet to be determined whether both isoforms have equivalent oncogenic capacity or have the same ability to alter cell motility. We have been unable to directly test the in vitro effect of high eEF1A1 expression because we have been unsuccessful at generating cell lines ectopically expressing high levels of eEF1A1 (D Purcell and JM Lee, unpublished observations). We speculate that high levels of eEF1A1 may be toxic to a cell or that some cellular feedback mechanism exists to prevent steady-state eEF1A1 levels from increasing beyond some threshold level. If eEF1A1, like eEF1A2, were oncogenic, we would expect that, like eEF1A2 (Lee, 2003) , the gene for eEF1A1 would be commonly amplified during oncogenesis and that some tumors would have high eEF1A1 mRNA expression. The eEF1A1gene, EEF1A1, maps to 6q14.1. This region is not frequently amplified in any malignancy and is deleted in squamous cell carcinoma, osteosarcoma and prostate cancer (Nathrath et al., 2002; Verhagen et al., 2002; Fitzsimmons et al., 2003) . This suggests that 6q14.1 contains a tumor suppressor. Similarly, we have not detected high expression of eEF1A1 in ovarian or breast tumors (Anand et al., 2002 and unpublished data) . Although the issue of eEF1A1's oncogenicity will require further investigation, based on the lack of tumor-specific EEF1A1 amplification or gene overexpression, we speculate that eEF1A1 is unlikely to be an oncogene, an idea consistent with the high level of eEF1A1 expression in normal tissue.
The ability of eEF1A2 to enhance migration and Akt activation suggests that eEF1A2 can be a target for anticancer therapy. The drug Aplidin, a derivative of didemnin B, an eEF1A-binding drug that inhibits GTP hydrolysis and translation elongation (Crews et al., 1994) , is currently undergoing clinical trials as an anticancer agent (Jimeno et al., 2004) . Because eEF1A2 is associated with poor prognosis in lung cancer (Li et al., 2005) , these patients would be predicted to benefit from eEF1A2 inactivation.
In summary, we report several novel functions of the eEF1A2 oncogene: eEF1A2 expression activates Akt and stimulates cell migration, invasion and filopodia formation in an Akt and PI3K-dependent pathway. These observations are consistent with the idea that eEF1A2 may promote tumor development through phosphatidyl-inositol signaling and actin remodeling.
Materials and methods
Cell lines
Rat2, Phoenix and BT549 cell lines were purchased from the American Tissue Culture Collection (ATCC, Manassas, VA, USA) and were grown in ATCC recommended media in 5% CO 2 at 371C in 1005 humidity. ROSE 199 cells were a gift of Dr Nelly Auersperg (UBC).
eEF1A2 activates Akt and actin remodeling A Amiri et al Plasmid constructs, siRNA and cell line preparation To generate an eEF1A2 retrovirus, full-length eEF1A2 with the C-terminal V5 tag was subcloned into pLXSN (Clontech, Mountain View, CA, USA) in EcoRI and XhoI sites. Retrovirus was generated in Phoenix Ampho cells. Fifty percent confluent BT549 were infected with 1 ml of viral supernatant in the presence of 4 mg polybrene (Sigma, Oakville, ON, Canada) and selected using G418 for 2 weeks. For eEF1A2 adenovirus generation, eEF1A2 was subcloned into pShuttle-IREShrGFP-1 in EcoRV and XhoI sites and the virus was manufactured by the central facility of the University of Ottawa. eEF1A2 and GFP control adenovirus were used at an multiplicity of infection (MOI) of 200. To produce eEF1A2-pCDNA 3.1, full-length eEF1A2 with the C-terminal V5 tag was subcloned into pcDNA 3.1/GS (Invitrogen, Burlington, ON, Canada) in EcoRI and XhoI sites. Lipofectamine 2000 (Invitrogen) was used for transfection as recommended by the manufacturer. Zeocin was used to select stable cell lines. The sequence of eEF1A2-siRNA is 5 0 -UCGAACUUCUCAAUG GUCCTT-3 0 . Transient transfection of siRNA was carried out using 4 ml of Lipofectamine 2000 and 5 ml of siRNA (100 nM).
Western blotting and immunoprecipitation
Cells were lysed using radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-Cl; pH 7.4, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM ethylenediaminetetraacetic acid (EDTA); pH 7.0, 150 mM NaCl) supplemented with 1% aprotonin, 1 mg/ml leupeptin, 50 mM NaF, 1 mM Na 3 VO 4 , 10 mg/ml pepstatin in ethanol, 1 mM phenylmethylsulfonyl flouride (PMSF) in dimethylsulfoxide (DMSO). Protein concentrations were determined by Bradford protein assay (Pierce, Rockford, IL, USA). Approximately 30 mg of protein extracts were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membrane. Anti-V5-horseradish peroxide (HRP) (Invitrogen), anti-FLAG (Sigma), b-actin (Sigma), Akt, phospho-Akt (Cell Signaling Technology, Danvers, MA, USA), goat anti-mouse IgG, HRP-conjugate (Upstate Cell Signaling Solutions) and anti-rabbit IgG, HRP-linked antibody (Cell Signaling Technology) were used according to the manufacturer's recommendations. Anti-eEF1A2 was manufactured as described (Kulkarni et al., 2006) and was used at 1:2000 dilution. Protein bands were visualized by chemiluminescence reagent enhanced chemiluminescence (ECL) (Amersham, Piscataway, NJ, USA). For PI3K/eEF1A2 interaction, BT549 cells were grown to 50% confluence and transduced with either GFP or eEF1A2 adenovirus (200 MOI) or left untransduced. After a 24-h infection period, cells were lysed in RIPA buffer. Out of the total protein, 100 mg from each case were pre-cleared with protein A agarose (Upstate Cell Signaling Solutions) or protein G sepharose (Amersham Biosciences, Piscataway, NJ, USA) for 1 h at 41C. 2-4 mg of anti-PI3K p85 (Upstate Cell Signaling Solutions, Charlottesville, VA, USA) or anti-V5 (Sigma) antibody were added to lysates and incubated overnight at 41C. The antibodies used for the Western blot are: PI3Kp85 (1:2000 in TBST), Y-pPI3Kp85 (Santa Cruz Biotechnology Inc.; 1:1000 in TBST, Santa Cruz, CA, USA), Flag M2 (Sigma; 1:2000 in TBST), and V5 (1:2000 in TBST), anti-rabbit IgG-HRP conjugate (Cell Signaling Technology; 1:5000 in TBST), and anti-mouse IgG (Upstate Cell Signaling Solutions; 1:5000 in TBST).
Immunofluorescence and video microscopy Cells were grown on coverslips coated with 50 mg/ml poly-Dlysin (Sigma) before fixation or video microscopy. For immunofluorescence staining, cells were fixed with 3.7% formaldehyde for 1 h and permeabilized by 0.1% Triton X-100 for 5 min. Following blocking with 2% goat serum and 1% bovine serum albumin (BSA), cells were labeled with Alexa Fluor 546 phalloidin (Molecular Probes, Burlington, ON, Canada) at 1:40 dilution for 1 h VASP monoclonal antibody (Transduction Laboratories, San Jose, CA, USA) was used at 1:50 dilution followed by secondary antibody Alexa Fluor 488-goat antibody at 1:450 dilution. After washing three times with PBS, cells were mounted on slides using fluorescent mounting medium (Dako Cytomation, Golstrup, Denmark). Slides were analysed by Leica DM IRE2 using 635 nm filter. Images were acquired by Retiga 12 bit camera (Leica, Richmond Hill, ON, Canada) and deconvoluted using Volocity 3.1 software (Improvision, Lexington, MA, USA). Images for time lapse microscopy were captured using the Axiovert 200 ZEISS microscope and ZEISS camera, and analysed by Axioversion Rel4.5 software.
Cell migration and invasion assays Cells were serum-starved overnight. The top chambers of 6.5-mm Corning Costar transwells (Corning, NY, New York, USA) were loaded with 0.2 ml of cells (5 Â 10 5 cells/ml) in serum-free media. Complete media 0.6 ml was added to the bottom wells and cells were incubated at 371C overnight. Cells on the top layer were removed and the images of the cells at the bottom of the membrane were captured using a Canon camera and a Zeiss Axio Vert microscope. The mean values were obtained from three individual experiments using Excel Microsoft software and subjected to Student's t-tests. For cell invasion assay, cells were serum-starved overnight. The 24-well cell culture inserts (8 mm pore size, BD Biosciences, San Jose, CA, USA) were loaded with 0.5 ml of cells (5 Â 10 5 cells/ml) in serum-free media. Complete media (0.5 ml) was added to the bottom wells and cells were incubated at 371C for about 2 days. Cells were fixed, stained and analysed as above.
Adhesion and spreading assays Adhesion and spreading assays were performed as described in Rodrigues et al. (2005) . Images were acquired by the Retiga 12 bit camera (Leica). Images for time-lapse microscopy for adhesion assay were captured using the Leica DM IRE2 microscope.
